Metagenomics and the human variome project can expect substantial boosts in the European Union's next round of science funding, starting this month.
The first calls for proposals went out on 22 December. For the health theme, the focus is on big biology. A planned metagenomics project, one large topic for the first call, aims to study the vast community of microbes living in the human body, which are thought to influence physiology, nutrition and immunity.
"There are some two kilograms of microorganisms living in the human body," says Dusko Ehrlich, a microbial geneticist at the French agricultural research agency INRA in Jouy-en-Josas. Most of them can't be grown in the lab: "We just don't know what's in there." Proposals are requested for projects to sequence the microbial genes present in the body, which are thought to outnumber our own genes by a factor of 100.
Another project earmarked for funding will support the global human variome project, which was launched in Melbourne, Australia, last June. The variome is the set of variations between different people's genomes, which influence the development of disease and drug side-effects. As yet there is no global system for collecting and sharing information on the human variome; FP7 promises to support one.
FP7 also provides €7.5 billion for a new Europe-wide funding agency called the European Research Council (ERC), which launches this month. The council will fund smaller projects that do not meet the industrial or societal goals required by the rest of the framework programme.
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The dark side of E. coli Last month, the president of fast-food chain Taco Bell appealed to his customers in fullpage ads in The New York Times and other US newspapers. "You can be confident our food is safe to eat, " his letter declared.
The ads were the fallout from a food-poisoning outbreak traced to the chain's restaurants, which has affected at least 70 people across five states. The culprit was Escherichia coli O157:H7 -the same as in another outbreak this September and October linked to Californian spinach, which infected nearly 200 across the country and killed three.
The outbreaks have thrown the spotlight on a bacterium that is difficult to detect and virtually impossible to treat or eradicate. "We see it more and more and we don't really know what to do about it, " says microbiologist John Fairbrother of the University of Montreal, Canada.
There are thousands of different strains of E. coli, most of which are harmless. But O157 can make a potent toxin and latch onto intestinal cells, giving it the ability to cause kidney failure and even death. The bugs live harmlessly in cows' large intestine and are thought to be ubiquitous in cattle lots. Bacteria shed in faeces contaminate meat in slaughterhouses or find their way onto vegetables grown near animals or irrigated with water contaminated with manure, as is thought to have happened with the tainted spinach. Lettuce is thought to have spread the Taco Bell outbreak.
There are now some promising research leads that might help prevent future outbreaks.
At a meeting earlier this year on pathogenic E. coli, veterinary researcher David Smith of the University of Nebraska, Lincoln, and his colleagues reported that a vaccine containing proteins from O157 cut the number of cows shedding bacteria by 60-70%. Canadian company Bioniche Life Sciences, based in Belleville, Ontario, has submitted the vaccine for regulatory approval in Canada, and plans to do so in the United States.
Other A radical project from the Public Library of Science (PLoS), the most prominent publisher in the open-access movement, is setting out to challenge academia's obsession with journal status and impact factors.
The online-only PLoS One, which launched on 20 December, will publish any paper that is methodologically sound. Supporters say the approach will remove some of the inefficiencies associated with current peer-review systems -but critics question whether a journal that eschews impact factors will manage to attract papers.
Among the 90 or so papers in PLoS One at its launch are reports on the meaning of wild gibbon songs and a mathematical model of rabies control. The authors of both papers say they chose PLoS One because they support open access, and because they wanted to be part of something new. "I think we're seeing one of the future directions of scientific publishing," says Colin Russell, a zoologist at the University of Cambridge, UK, and an author of the rabies paper.
Every paper submitted to the journal is reviewed by at least one member of PLoS One's editorial board of over 200 researchers, but only to check for serious flaws in the way the experiment was conducted and analysed. In contrast to almost all other journals, referees ignore the significance of the result. Notable papers will instead be highlighted by the attention they attract after publication.
Visitors to the PLoS One website can, for example, attach comments to specific parts of a paper and rate the paper as a whole. Data from those systems, as well as download and citation statistics, will then allow PLoS One's editors to identify and promote the papers that researchers are talking about. "We're trying to make a journal where papers are not the end point, they are the start of a discussion," says PLoS One managing editor Chris Surridge, based in Cambridge, UK.
The journal will initially publish 10-15 papers a week, but this could reach a few hundred each month, says Surridge. The system makes sense, he says, because a single review process avoids the time wasted when papers are rejected from high-ranking journals and reviewed again elsewhere. Others add that the journal's decision to accept papers from all areas of science could benefit authors of interdisciplinary studies, whose work is often rejected by subject-specific journals.
But PLoS One faces some significant challenges. Many new journals struggle to attract papers until they are given an impact factor (a measure of the citations its papers receive), but a journal that accepts everything can't usefully be classified in this way. Critics also point out that referees may be reluctant to review potentially trivial papers, and that existing journals have had little luck persuading readers to comment on papers after publication.
Yet Surridge is bullish about his journal's chances. He thinks referees will appreciate the approach, as it will cut the number of reviews that scientists as a whole have to make. He adds that existing attempts to encourage comments don't reflect the way scientists actually read papers -something he aims to remedy by allowing visitors to highlight and annotate different sections of text. Surridge also says that other systems offered little reward to researchers; PLoS One will allow comments to be rated by others, letting users establish status accordingly. 
Rival publishers have suggested that
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Open-access journal will publish first, judge later "We're trying to make a journal where papers are not the end point, they are the start of a discussion." reductions will protect humans. Just ten cells of O157 are enough to infect a person, compared with hundreds of thousands needed for a Salmonella or cholera infection. "It's a very different standard for foods to meet," says James Kaper, an E. coli expert at the University of Maryland, Baltimore. He notes that irradiation would rid food of the bacteria but that the public, food industry and food-safety regulators have been reluctant to adopt it.
So researchers are also working on treatments, for example with antibodies that inactivate the toxin. (Antibiotics aren't recommended for E. coli because by the time the infection is diagnosed, the bugs have usually released so much toxin that killing them doesn't help.) But researchers admit that the demand for such drugs is likely to be low.
Perhaps an underestimated problem are other pathogenic E. coli strains, including O26, O111 and O145. These can also cause serious food poisoning but are more likely to go unnoticed, because lab tests are more difficult or not routine. These strains are more common outside the United States; in Italy, for example, most cases of E. coli food poisoning probably go undetected, says Alfredo Caprioli, who directs the E. coli reference lab at the Istituto Superiore di Sanità in Rome. There is intense interest in finding the exact combination of genes that make strains harmful to humans and quick ways to test for them.
Ultimately researchers must find the critical points in the food supply at which intervention can most reduce contamination, says food scientist Don Schaffner of Rutgers University, New Jersey. "Obviously we haven't studied it enough to solve the problem. " 
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